Hunan Er Kang Pharmaceutical - Asset Resilience Ratio

Latest as of June 2025: 1.19%

Hunan Er Kang Pharmaceutical (300267) has an Asset Resilience Ratio of 1.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300267 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥60.00 Million
≈ $8.78 Million USD Cash + Short-term Investments

Total Assets

CN¥5.05 Billion
≈ $738.96 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Hunan Er Kang Pharmaceutical's Asset Resilience Ratio has changed over time. See Hunan Er Kang Pharmaceutical (300267) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hunan Er Kang Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300267 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥60.00 Million 1.19%
Total Liquid Assets CN¥60.00 Million 1.19%

Asset Resilience Insights

  • Limited Liquidity: Hunan Er Kang Pharmaceutical maintains only 1.19% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hunan Er Kang Pharmaceutical Industry Peers by Asset Resilience Ratio

Compare Hunan Er Kang Pharmaceutical's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Hunan Er Kang Pharmaceutical (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Hunan Er Kang Pharmaceutical.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.31% CN¥120.00 Million
≈ $17.56 Million
CN¥5.20 Billion
≈ $760.88 Million
+2.31pp
2023-12-31 0.00% CN¥118.60K
≈ $17.35K
CN¥5.48 Billion
≈ $801.76 Million
-1.95pp
2022-12-31 1.95% CN¥114.12 Million
≈ $16.70 Million
CN¥5.86 Billion
≈ $856.87 Million
+1.87pp
2020-12-31 0.08% CN¥5.30 Million
≈ $775.97K
CN¥6.55 Billion
≈ $958.00 Million
-2.00pp
2015-12-31 2.08% CN¥100.00 Million
≈ $14.63 Million
CN¥4.80 Billion
≈ $702.59 Million
--
pp = percentage points

About Hunan Er Kang Pharmaceutical

SHE:300267 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.32 Billion
CN¥8.99 Billion CNY
Market Cap Rank
#7929 Global
#1981 in China
Share Price
CN¥4.36
Change (1 day)
+3.81%
52-Week Range
CN¥2.93 - CN¥4.69
All Time High
CN¥17.60
About

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for i… Read more